| 18th week of 2016 patent applcation highlights part 27 |
| Patent application number | Title | Published |
|---|
| 20160122699 | CELL SEPARATION AND CULTURE DEVICE - The present invention provides a cell separation and culture device, comprising: a porous substrate; and a patterned carbon powder layer having a plurality of hollow regions, formed on an upper surface of the porous substrate by a forming manner; wherein the thickness of the patterned carbon powder layer is 0.04-0.08 mm. By the features of the present invention, the cell separation and culture device of the present invention is able to separate, detect or culture cells with various size and shape. The cell separation and culture device of present invention also could simplify the process of cell separation, detection and culture; therefore, we could take very short time to accomplish. | 2016-05-05 |
| 20160122700 | DISPERSING FEEDSTOCKS AND PROCESSING MATERIALS - Biomass feedstocks (e.g., plant biomass, animal biomass, and municipal waste biomass) are processed to produce useful products, such as fuels. For example, systems are described that can convert feedstock materials to a sugar solution, which can then be fermented to produce ethanol. Biomass feedstock is dispersed in a liquid medium and then saccharified. | 2016-05-05 |
| 20160122701 | Methods, Devices and Systems for Algae Lysis and Content Extraction - Described herein are devices, systems and methods for lysing algae cells, for production of a lysate product such as a biofuel. The systems and methods use a passive device that lyses the cells through flow configurations, geometries, and surfaces that would induce different stresses and negative pressure on the microalgae cells. When the stress is designed to exceed the mechanical strength of the microalgae cells, the cells are lysed, causing, e.g., lipid release which can be used to produce biofuels. Through an internally-created computational framework, the concept is validated and can be optimized for the lowest energy input with the highest level of lipid release. Also provided herein are computer-implemented methods for optimizing lysis in such systems and computer-readable media containing instructions for performing the computer-implemented methods. | 2016-05-05 |
| 20160122702 | Method for Determining Cell State and Autoanalyzer Using Said Method - There is provided a method for noninvasively evaluating the cell state (proliferation, multi-layering, and differentiation) of a cell sheet as a mimic tissue at the time of culturing the cell sheet. The method is characterized in that an analysis of an amino acid is conducted with the use of the culture supernatant of a cell sheet to monitor a change in the concentration of any amino acid selected from a group of 5-species of amino acids (Ile, Val, Ser, Leu, and Ala), thereby making a determination. | 2016-05-05 |
| 20160122703 | METHOD AND SYSTEM FOR TREATING ORGANIC WASTE AND WASTEWATER - An organic waste and wastewater treatment method and system that quickly and cost-effectively removes most organic materials from a waste or wastewater while generating a gaseous byproduct that can be used for heat or electricity generation. The method and system begins with a maceration and/or screening step that reduces waste particle size. Then, the waste is pumped through orifice(s) under high pressure to emulsify the waste and covert it to a slurry. The slurry is then treated in a horizontal anaerobic digester with flexible support material for microbial attachment to remove organic materials. | 2016-05-05 |
| 20160122704 | METHOD FOR SEPARATION OF SPORADIC CELLS FROM BODY FLUIDS, AND APPARATUS FOR CARRYING OUT SAID METHOD - Method for gentle separation of viable sporadic cells from body fluids such as blood, from malignant effusions, bronchoalveolar lavage fluid, peritoneal lavage fluid and amniotic fluid, based on a filter membrane which is in an intimate contact with an absorbent material. Using the present method it is possible to isolate for example circulating and disseminated tumor cells, endometrial cells and circulating trophoblast cells, allowing subsequent detection, quantification, characterization and especially culturing of said cells. An apparatus for carrying out the method is further disclosed. | 2016-05-05 |
| 20160122705 | DUAL-COMPARTMENT BIOREACTOR FOR USE IN WASTEWATER TREATMENT AND ALGAL PRODUCTION - A dual compartment bioreactor system includes a heterotrophic bioreactor, an autotrophic bioreactor, and a membrane between the autotrophic bioreactor and the heterotrophic bioreactor. The autotrophic bioreactor includes a transparent outer wall. Each population benefits from the products of the metabolism of the other. Methods for wastewater treatment and algal production utilize the system. | 2016-05-05 |
| 20160122706 | METHODS OF PRODUCING ALGAL CELL CULTURES AND BIOMASS, LIPID COMPOUNDS AND COMPOSITIONS, AND RELATED PRODUCTS - The present invention is directed to methods of producing algal biomass and algal cell cultures, and lipid compounds and compositions thereof, including fatty acids, carotenoids and fat soluble vitamins. The present invention is further directed to methods of preparing related food products and industrial and pharmaceutical compositions. In various exemplary embodiments, the methods comprise growing algae in a juice based medium, including a medium that contains natural nitrogen or a medium that is free of chemical additives and preservatives, to produce algal cell cultures, algal biomass, algae derived lipid compounds and compositions, and related products, all that can be certified organic. | 2016-05-05 |
| 20160122707 | PROTEIN MODIFICATION OF LIVING CELLS USING SORTASE - Non-genetically engineered mammalian cells modified by sortase-mediated conjugation of an agent thereto are provided. Methods of conjugating agents to nongenetically engineered mammalian cells using sortase are provided. Methods of using the cells, e.g. a method of modulating an immune response of a subject to an entity of interest, a method of neutralizing a substance in the body of a subject, a method of treating a subject in need of treatment for deficiency of a protein, and a method of treating a subject in need of treatment for a disease, are provided. | 2016-05-05 |
| 20160122708 | SMALL MOBILE STEM CELLS (SMS) AND USES THEREOF - The presently disclosed subject matter relates, in general, to the identification, isolation, and use of a population of stem cells isolated from umbilical cord blood, peripheral blood and/or other sources and that are referred to herein as Small Mobile Stem cells (short: SMS). More particularly, the presently disclosed subject matter relates to isolating said SMS stem cells and employing the same, optionally after in vitro manipulation, to treat tissue and/or organ damage in a subject in need thereof. | 2016-05-05 |
| 20160122709 | STEM CELL BANK FOR PERSONALIZED MEDICINE - The present invention relates to a stem cell bank which stores stem cells collected from individuals throughout their entire life. The stem cell bank of the present invention stores stem cells of various types, which are obtained from a plurality of sources from a single individual. The present invention further relates to methods of personalized medicine that utilizes cells stored in a bank of the present invention, and to compositions of stem cells for the treatment of various types of diseases. | 2016-05-05 |
| 20160122710 | METHOD AND PHARMACEUTICAL COMPOSITION FOR CONTINUOUSLY MAINTAINING GROWTH OF A MOTOR NEURON PROGENITOR CELL - This present invention provides a method for continuously maintaining growth of a motor neuron progenitor cell and a pharmaceutical composition. Wherein, the method for continuously maintaining growth of a motor neuron progenitor cell is to culture the motor neuron progenitor cell in an environment which is constructed by the olfactory ensheathing cells to make the motor neuron progenitor cell sustain the ability to self-replicate and to be induced for differentiating into mature neuron, and therefore to elaborate the effect to protect the motor neuron. The motor neuron progenitor cell produced from the method disclosed in this present invention can be an effective ingredient of the pharmaceutical composition for treating related diseases of damaged motor neuron. | 2016-05-05 |
| 20160122711 | CHEMICAL DIFFERENTIATION OF PLURIPOTENTSTEM CELLS INTO RETINAL EPITHELIAL CELLS - The present invention is based in part on a chemically defined method of generating retinal epithelial cells and retinal pigmented epithelial cells from human pluripotent stem cells (hpSCs). The present invention also provides methods and kits for treating degenerative eye disorders. | 2016-05-05 |
| 20160122712 | CELL PROGRAMMING - The present invention is concerned with methods for reprogramming of mammalian somatic cells and in particular to reprogramming of mature mammalian somatic cells into multi-potent precursor cells. | 2016-05-05 |
| 20160122713 | GENETICALLY-MODIFIED MICRO-ORGAN SECRETING A THERAPEUTIC PEPTIDE AND METHODS OF USE THEREOF - Provided herein is a genetically-modified micro-organ that provides a sustained delivery of a therapeutic peptide. The genetically-modified micro-organ may comprise a viral vector or expression cassette comprising at least two nucleic acid sequences encoding the therapeutic peptide separated by a cleavable linker. Further provided herein is a method of treating or preventing a disease or disorder in a human subject that can be treated or prevented by administration of a therapeutic peptide over a sustained time period using the genetically-modified micro-organ described herein. | 2016-05-05 |
| 20160122714 | SERUM-FREE MEDIUM CONTAINING PDGF FOR DS CELLS - The problem to be solved by the present invention is to provide a serum-free medium suitable for culturing of DS cells. The present invention relates to a serum-free medium for culturing of DS cells containing platelet-derived growth factor (PDGF), or to a method for culturing of dermal sheath (DS) cells, using serum-free medium comprising PDGF. | 2016-05-05 |
| 20160122715 | GENERATION OF CYTOTOXIC TUMOR SPECIFIC CELL LINES AND USES THEREOF - An in-vitro method of activating T cells is disclosed. The method comprises incubating T cells with pathogenic cells in the presence of a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in SEQ ID NO: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of PLIF to human leukocytes under conditions which allow expansion of the T cells. | 2016-05-05 |
| 20160122716 | METHOD OF EFFICIENTLY INDUCING CARDIOMYOCYTES - The present invention provides a method for efficiently producing cardiomyocytes from pluripotent stem cells, which method comprises the steps of dissociating embryoid bodies obtained during the production process, and allowing reaggregation of the resulting cells to allow formation of embryoid bodies. | 2016-05-05 |
| 20160122717 | DIFFERENTIATION OF PLURIPOTENT STEM CELLS AND CARDIAC PROGENITOR CELLS INTO STRIATED CARDIOMYOCYTE FIBERS USING LAMININS LN-511, LN-521 AND LN-221 - The present disclosure describes methods of differentiating cardiomyocyte progenitor cells and mature cardiomyocyte cells from pluripotent stem cells. The methods may include differentiating pluripotent stems cells on a substrate including (i) laminin-511 or 521 and (ii) laminin 221. The mature cardiomyocyte cells produced by the method may form a human heart muscle cell line for use in regenerative cardiology. | 2016-05-05 |
| 20160122718 | CULTURE MEDIUM COMPOSITION FOR MATURATING CARDIOMYOCYTES DERIVED FROM PLURIPOTENT MAMMALIAN STEM CELLS - The current disclosure relates to a culture medium, different methods to generate adult-like cardiomyocytes from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC) using the medium, in particular from stem cells that differentiated into (foetal) cardiomyocytes, and to kits comprising the medium, or the medium together with differentiated (foetal) cardiomyocytes derived from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC). | 2016-05-05 |
| 20160122719 | METHODS AND COMPOSITIONS FOR PREPARING CARDIOMYOCYTES FROM STEM CELLS AND USES THEREOF - The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries. | 2016-05-05 |
| 20160122720 | METHOD OF EFFICIENTLY ESTABLISHING INDUCED PLURIPOTENT STEM CELLS - The invention provides a method of producing iPS cells, which comprises the steps of (i) introducing reprogramming factors into somatic cells; (ii) culturing the cells obtained in step (i) for more than 11 days and not more than 29 days; (iii) sorting TRA-1-60-positive cells from the cells obtained in step (ii); (iv) culturing the TRA-1-60-positive cells sorted in step (iii); (v) transferring a colony obtained in step (iv) to another culture vessel; and (vi) culturing the cells obtained in step (v), thereby obtaining iPS cells. The cells obtained in step (v) are preferably subcultured 10 times or more. The invention also provides a method of producing a population of differentiated cells that has a reduced rate of residual undifferentiated cells, which comprises inducing differentiation of the iPS cells obtained by the above-mentioned method. | 2016-05-05 |
| 20160122721 | USE OF RNA FOR REPROGRAMMING SOMATIC CELLS - The present invention provides methods for de-differentiating somatic cells into stem-like cells without generating embryos or fetuses. More specifically, the present invention provides methods for effecting the de-differentiation of somatic cells to cells having stem cell characteristics, in particular pluripotency, by introducing RNA encoding factors inducing the de-differentiation of somatic cells into the somatic cells and culturing the somatic cells allowing the cells to de-differentiate. | 2016-05-05 |
| 20160122722 | TISSUE STRUCTURE AND PREPARATION METHOD THEREOF - A tissue structure for enabling comprehensive understanding of gene patterns of mature cells and a method of preparing the tissue structure are provided. A tissue structure is obtained by co-culturing an endodermal, ectodermal, or mesodermal cell derived from a stem cell and at least one cell and/or factor selected from the group consisting of a vascular cell, a mesenchymal cell, a factor secreted by a vascular cell, a factor secreted by a mesenchymal cell, and a factor secreted when both a vascular cell and a mesenchymal cell exist. A value obtained by assay of a plurality of functions using a Pearson product-moment correlation coefficient is closer to a value of a cell or biological tissue sampled from an adult than a value of a cell or biological tissue sampled from a fetus. | 2016-05-05 |
| 20160122723 | ENGINEERED THREE-DIMENSIONAL SKIN TISSUES, ARRAYS THEREOF, AND METHODS OF MAKING THE SAME - Disclosed are bioprinted, three-dimensional, biological skin tissues comprising: a dermal layer comprising dermal fibroblasts; and an epidermal layer comprising keratinocytes, the epidermal layer in contact with the dermal layer to form the three-dimensional, engineered, biological skin tissue. Also disclosed are arrays of engineered skin tissues and methods of making engineered skin tissues. | 2016-05-05 |
| 20160122724 | Recombinant Baculovirus Expression Vector and Cell - A recombinant baculovirus expression vector or cell comprising an engineered baculovirus fp25k gene with one to three modified or mutated spots, the modified spots comprise the two 7-adenine mononucleotide repeats (MNR) and the 10 | 2016-05-05 |
| 20160122725 | USE OF BACTERIOPHAGES - We disclose the use of a strain of bacteriophages in the manufacturing of a preparation for improving the state of health of patients infected with adenoviruses, wherein preferably the preparation produced is used for the treatment or prevention of adenoviral infections, particularly those caused by HAdV, preferably HAdV-5. | 2016-05-05 |
| 20160122726 | INFLUENZA VIRUS REASSORTMENT - The invention provides reassortant influenza strains. | 2016-05-05 |
| 20160122727 | MESSENGER RNA BASED VIRAL PRODUCTION - The present invention provides methods for producing recombinant viral particles based on the use of exogenous mRNAs to supply various helper factors for assembly of viral particles, purified recombinant viral particles produced using such methods, and methods of using such viral particles. | 2016-05-05 |
| 20160122728 | IPN VACCINE - The present invention relates to a live avirulent infectious pancreatic necrosis virus which has been shown to be genetically stable in biological studies. Fish exposed to said virus turn out positive for the virus without showing any signs of disease and the avirulent virus has also been shown to protect the fish against IPN for an extended period of time after administration. Thus, a vaccine comprising said virus and said virus for the prophylaxis or treatment of infectious pancreatic necrosis disease are also part of the present invention. | 2016-05-05 |
| 20160122729 | RECOMBINANT PHAGE AND METHODS - This disclosure provided methods of cloning a phage genome. Also provided are methods of making a recombinant phage genome. In some embodiments the phage genome is engineered to comprise a heterologous nucleic acid sequence, for example a sequence comprising an open reading frame. In some embodiments the phage genome is cloned in a yeast artificial chromosome. Recombinant phage genomes and recombinant phage are also provided. In some embodiments the methods are high throughput methods such as methods of making aa plurality of recombinant phage genomes or recombinant phage. Collections of recombinant phage genomes and recombinant phage are also provided. | 2016-05-05 |
| 20160122730 | NOVEL MOLECULES OF THE CARD-RELATED PROTEIN FAMILY AND USES THEREOF - Novel CARD-9, CARD-10, or CARD-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-9, CARD-10, or CARD-11 proteins, the invention further provides CARD-9, CARD-10, or CARD-11, fusion proteins, antigenic peptides and anti-CARD-9, CARD-10, or CARD-11 antibodies. The invention also provides CARD-9, CARD-10, or CARD-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-9, CARD-10, or CARD-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 2016-05-05 |
| 20160122731 | THERAPEUTIC STRATEGIES TO TREAT CNS PATHOLOGY IN MUCOPOLYSACCHARIDOSES - The invention provides for nucleotide sequences encoding for a chimeric sulfatase, viral vectors expressing such sequences for gene therapy and pharmaceutical uses of the chimeric expressed protein. The invention is particularly applied in the therapy of mucopolysaccharidosis, preferably type IIIA. | 2016-05-05 |
| 20160122732 | HIGH ACTIVITY MUTANTS OF COCAINE ESTERASE FOR COCAINE HYDROLYSIS - The Bacterial cocaine esterase (CocE) mutants disclosed herein each have enhanced catalytic efficiency for (−)-cocaine, as compared to CocE mutants in the prior art, including CocE mutant E172-173. The presently-disclosed subject matter further includes a pharmaceutical composition including a mutant of bacterial cocaine hydrolase, as described herein, and a suitable pharmaceutical carrier. The presently-disclosed subject matter further includes a method of treating a cocaine-induced condition comprising administering to an individual an effective amount of a mutant of bacterial cocaine hydrolase variant, as disclosed herein, to accelerate cocaine metabolism and produce biologically inactive metabolites. | 2016-05-05 |
| 20160122733 | METHOD OF TREATING GLYCOGEN STORAGE DISEASE - The disclosure relates, in general, to Glycogen Storage Disease and, in particular, to a method of treating Glycogen Storage Disease and to compounds and compositions suitable for use in such a method. | 2016-05-05 |
| 20160122734 | VARIANTS OF CELLOBIOHYDROLASES - Disclosed are a number of homologs and variants of | 2016-05-05 |
| 20160122735 | VARIANTS OF CELLOBIOHYDROLASES - Disclosed are a number of homologs and variants of | 2016-05-05 |
| 20160122736 | CHEMICALLY MODIFIED SOPHOROLIPIDS AND USES THEREOF - The present disclosure provides a sophorolipid composition that can be used for inducing protein expression in a fermentation host. The sophorolipid composition described herein can be prepared from a natural sophorolipid mixture. Acid treatment of the natural sophorolipid mixture results in a mixture of monoacetylated, deacetylated, and/or diacetylated sophorolipids. The chemically modified sophorolipid composition, or isolated components of the chemically modified sophorolipid composition, can be used as inducers for protein production in filamentous fungi. | 2016-05-05 |
| 20160122737 | XYLANASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to xylanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 2016-05-05 |
| 20160122738 | NOVEL METALLOPROTEASES - Aspects of the present compositions and methods relate to novel metalloproteases, polynucleotides encoding the novel metalloproteases, and compositions and methods for use thereof. | 2016-05-05 |
| 20160122739 | FACTOR IX VARIANTS AND METHODS OF USE THEREFOR - Modified Factor IX (FIX) polypeptides, nucleic acid encoding the same, and methods of generating modified Factor IX polypeptides are provided. Also provided are pharmaceutical compositions that contain the modified Factor IX polypeptides, methods of treatment using modified Factor IX polypeptides, and assay for Factor IX activity. | 2016-05-05 |
| 20160122740 | FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND METHOD FOR ITS PRODUCTION - Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide. | 2016-05-05 |
| 20160122741 | Molecules Associated with Fatty Acid Biosynthetic Pathways and Uses Thereof - The present disclosure relates in part to recombinant microorganisms that include non-native genes encoding PUFA-PKS polypeptides, and to methods of making and using such microorganisms for producing at least one PUFA. In particular, the disclosure further relates to methods and related materials useful for the production of at least one PUFA by heterologous expression of the nucleic acid sequences disclosed herein encoding PUFA-PKS polypeptides. | 2016-05-05 |
| 20160122742 | PROTEIN INVOLVED IN DNA REPLICATION, AND MODULATION OF ITS ACTIVITY - A composition including at least a protein consisting of an amino acid sequence as set forth in SEQ ID NO: 1, or a salt or a solvate thereof, in association with a pharmaceutically acceptable carrier, for its use for treating pathologies link to DNA replication. | 2016-05-05 |
| 20160122743 | METHODS FOR REMOVING VIRAL CONTAMINANTS FROM PANCREATIC EXTRACTS - Methods for screening pancrelipase for RNA virus contamination comprise removing free viral RNA from the pancrelipase, denaturing any viruses in the pancrelipase to release encapsidated RNA into the pancrelipase milieu, and detecting this released RNA. Removal of free viral RNA may comprise treating pancrelipase with RNase and DNase or precipitating the protein fraction of pancrelipase with a salt that precipitates the protein fraction while leaving nucleic acids such as RNA in solution. Pancrelipase substantially devoid of free nucleic acid is also provided. | 2016-05-05 |
| 20160122744 | BIOMOLECULE DRYING PROCESS FOR LONG-TERM STORAGE - The present invention relates to a method for producing a storable dry composition of biomolecule. First a composition is dispensed on a surface. The composition comprises at least a biomolecule, at least a liquid volatile component, at least a polysaccharide being designed for forming together with the at least a biomolecule and a part of the at least a liquid volatile component a matrix displaying a glass transition temperature Tg. Secondly, at least a part of the liquid volatile component is evaporated by adjusting the temperature of said composition to allow the formation of the matrix. Said evaporation step is initiated at an initial temperature T1, and finished up at a final temperature T2, said final temperature T2 being above said initial temperature T1. | 2016-05-05 |
| 20160122745 | METHOD AND SYSTEM FOR AQUACULTURE OR REDUCING BIOFOULING - An aquaculture method and a method for reducing biofouling of vessels or submerged structures, the method comprising broadcasting into the marine environment sound at a frequency or in a frequency range effective to attract one or more marine species to the sound source. | 2016-05-05 |
| 20160122746 | METHOD OF NONSPECIFIC TARGET CAPTURE OF NUCLEIC ACIDS - Methods for capturing a target nucleic acid from a sample by using a capture probe that binds nonspecifically to the target nucleic acid and binds specifically to an immobilized probe via a specific binding pair that has one member on the capture probe and one member on the immobilized probe are disclosed. Compositions that include a capture probe that binds nonspecifically to a target nucleic acid and specifically to an immobilized probe via binding of members of a specific binding pair in a solution phase of a reaction mixture are disclosed. | 2016-05-05 |
| 20160122747 | TARGET ANTIGEN DISCOVERY, PHENOTYPIC SCREENS AND USE THEREOF FOR IDENTIFICATION OF TARGET CELL SPECIFIC TARGET EPITOPES - The invention provides methods and compositions for identifying binding polypeptides (e.g., antibodies or antigen binding fragments thereof) that specifically binds to a cell-surface antigen. The methods of the invention generally comprise contacting a variegated nucleic acid-display library of binding polypeptides with a cell-surface antigen displayed on the exterior surface of a cell; and isolating from the library at least one library member that specifically binds to the cell-surface antigen on the exterior surface of the cell. | 2016-05-05 |
| 20160122748 | SCALABLE METHOD FOR ISOLATION AND SEQUENCE-VERIFICATION OF OLIGONUCLEOTIDES FROM COMPLEX LIBRARIES - A novel method for preparing sequence-verified oligonucleotides is disclosed. In particular, the invention relates to a simple, affordable, and scalable method that combines high-throughput mating of yeast clones, a unique selectable system for combining DNA sequences in yeast, and next-generation sequencing. This method allows sequence-verified oligonucleotides to be readily isolated from complex libraries. | 2016-05-05 |
| 20160122749 | SCREENING FOR INHIBITORS OF RIBOSOME BIOGENESIS - The invention relates to a method and a prokaryotic cell for identifying a compound, which interferes with ribosome biogenesis, assembly and/or degradation. The cell expresses a first fusion protein comprising a first ribosomal protein, an amino acid linker and a first fluorescent protein, and a second fusion protein comprising a second ribosomal protein, an amino acid linker and a second fluorescent protein. The invention further relates to a gene construct comprising a first element encoding a first ribosomal protein fused to a first fluorescent protein by an amino acid linker, and a second element encoding a second ribosomal protein fused to a second fluorescent protein by an amino acid linker. | 2016-05-05 |
| 20160122750 | ACCELERATED DIRECTED EVOLUTION OF MICROBIAL CONSORTIA FOR THE DEVELOPMENT OF DESIRABLE PLANT PHENOTYPIC TRAITS - The disclosure relates to methods for the screening, identification, and/or application of one or more microorganisms of use in imparting one or more beneficial properties to one or more plants. | 2016-05-05 |
| 20160122751 | NUCLEIC ACID-TAGGED COMPOSITIONS AND METHODS FOR MULTIPLEXED PROTEIN-PROTEIN INTERACTION PROFILING - Methods and compositions for multiplexed protein-protein interaction profiling (e.g., immunoprofiling), based on nucleic acid tagging of polypeptides (e.g., by RNA display) are described. In some embodiments the described compositions and methods utilize a library of prey polypeptide targets linked to prey RNAs encoding them, and a population of bait polypeptides, e.g., a mixture of antibodies, that bind to one or more of the prey polypeptide targets and are used to isolate and identify the bound prey polypeptide targets by amplification of their associated prey RNAs and sequencing of the corresponding cDNAs. In other embodiments the prey polypeptide targets are linked to DNA Bar Codes, which serve as unique identifiers of the tagged polypeptide. | 2016-05-05 |
| 20160122752 | Methods for Obtaining Information from Single Cells Within Populations Using DNA Origami Nanostructures Without the Need for Single Cell Sorting - Methods for construction of DNA origami nanostructures, as well as for binding, isolation, linking, and deep sequencing information, such as both of TCR alpha and beta CDR3 mRNA, from individual cells within a mixed population of cells without the need for single cell sorting. | 2016-05-05 |
| 20160122753 | HIGH-THROUGHPUT RNA-SEQ - The present invention relates generally to methods for single-cell nucleic acid profiling, and nucleic acids useful in those methods. For example, it concerns using barcode sequences to track individual nucleic acids at single-cell resolution, utilizing template switching and sequencing reactions to generate the nucleic acid profiles. These methods and compositions are also applicable to other starting materials, such as cell and tissue lysates or extracted/purified RNA. | 2016-05-05 |
| 20160122754 | Arrays and Methods of Use - Methods are provided for producing a molecular array comprising a plurality of molecules immobilized to a solid substrate at a density which allows individual immobilised molecules to be individually resolved, wherein each individual molecule in the array is spatially addressable and the identity of each molecule is known or determined prior to immobilization. The use of spatially addressable low density molecular arrays in single molecule detection and analysis techniques is also provided. Novel assays and methods are also provided. | 2016-05-05 |
| 20160122755 | Compositions, Methods and Apparatus for Oligonucleotides Synthesis - Aspects of the invention relate to methods, compositions for synthesizing oligonucleotides having a predefined sequence. | 2016-05-05 |
| 20160122756 | COMPOSITIONS AND METHODS FOR DIRECTIONAL NUCLEIC ACID AMPLIFICATION AND SEQUENCING - The invention provides methods and compositions, including kits, for directional nucleic acid amplification and sequencing. The invention further provides methods and compositions for the construction of directional cDNA libraries. | 2016-05-05 |
| 20160122757 | siRNA TARGETING HSR1 - The invention provides siRNA molecules and LNA antisense oligonucleotides, which target Heat Shock RNA (HSR1) and effectively inhibit stress response in a cell, and their use for treatment of various diseases. | 2016-05-05 |
| 20160122758 | AGENTS FOR DOWNREGULATION OF THE ACTIVITY AND/OR AMOUNT OF BCL-XL AND/OR BCL-W - A method of treating an inflammatory or fibrotic disease in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which down-regulates an activity and/or an amount of Bcl-xL and/or Bcl-w and/or p21, with the proviso that the inflammatory disease is not cancer. | 2016-05-05 |
| 20160122759 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES - Methods, kits and devices for dosing a subject to reduce a hypersensitivity response to a lipid-formulated nucleic acid (e.g., RNA) molecule are disclosed. | 2016-05-05 |
| 20160122760 | COMPOSITIONS AND METHODS FOR MODULATING FOXP3 EXPRESSION - Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of FOXP3. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of FOXP3. Methods for modulating expression of FOXP3 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of FOXP3. | 2016-05-05 |
| 20160122761 | COMPOSITIONS AND METHODS FOR MODULATION OF TARGET NUCLEIC ACIDS - The present disclosure pertains generally to chemically-modified oligonucleotides for use in research, diagnostics, and/or therapeutics. In certain embodiments, the present disclosure describes compounds and methods for the modulation of a target nucleic acid. In certain embodiments, the present disclosure describes compounds and methods for the modulation of Apoliprotein C-III expression. | 2016-05-05 |
| 20160122762 | METHODS OF TREATING ATHEROSCLEROSIS - Certain embodiments of the invention provide a method of treating endothelial dysfunction, cardiovascular disease and/or atherosclerosis in a mammal, comprising administering an effective amount of a micro-RNA-204-5p inhibitor to the mammal. | 2016-05-05 |
| 20160122763 | REPLICATION FACTOR C-40 (RFC40/RFC2) AS A PROGNOSTIC MARKER AND TARGET IN ESTROGEN POSITIVE AND NEGATIVE AND TRIPLE NEGATIVE BREAST CANCER - The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs, miRNAs, and shRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided. | 2016-05-05 |
| 20160122764 | RESPIRATORY DISEASE-RELATED GENE SPECIFIC SIRNA, DOUBLE-HELICAL OLIGO RNA STRUCTURE CONTAINING SIRNA, COMPOSITON CONTAINING SAME FOR PREVENTING OR TREATING RESPIRATORY DISEASE - The present invention relates to a gene specific siRNA related with respiratory diseases, particularly, to a gene specific siRNA related with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), and a highly efficient double-helical oligo RNA structure containing the same, wherein the double-helical oligo RNA structure has a structure in which hydrophilic and hydrophobic materials are bonded at the both ends of the double-helical RNA (siRNA) using a simple covalent bond or a linker-mediated covalent bond to be effectively transferred into a cell, and may be converted into nanoparticles by the hydrophobic interaction of the double-helical oligo RNA structure in a solution. It is desirable that the siRNA contained in the double-helical oligo RNA structure is a siRNA specific to a CTGF, Cyr61, or Plekho1, which are genes related with respiratory diseases, particularly idiopathic pulmonary fibrosis and COPD. In addition, the present invention relates to a method for producing the double-helical oligo RNA structure and a pharmaceutical composition containing the double-helical oligo RNA structure for preventing or treating respiratory diseases, particularly idiopathic pulmonary fibrosis and COPD. | 2016-05-05 |
| 20160122765 | QSOX1 AS AN ANTI-NEOPLASTIC DRUG TARGET - The present invention provides methods for tumor treatment by administering an inhibitor of quiescin sulfhydryl oxidase 1 (QSOX1), compositions comprising such inhibitors, and methods for identifying such inhibitors. | 2016-05-05 |
| 20160122766 | Methods and Compositions for Reducing Immunosupression by Tumor Cells - The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof. | 2016-05-05 |
| 20160122767 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA - The present invention relates to methods and pharmaceutical compositions for the treatment of Erythropoietic Protoporphyria. In particular, the present invention relates to a method for increasing the amount of functional FECH in a erythroid cell carrying the hypomorphic allele IVS3 48C/T (rs2272783) in trans to a deleterious mutation in the FECH gene comprising the step of consisting of bringing the erythroid cell into contact with at least one antisense oligonucleotide (ASO) comprising the sequence as set forth by SEQ ID NO: 2 (5′ gcagcctgagaaatgtttt 3′) to prevent splicing of the cryptic exon inserted into the mutant IVS3 48C/T (rs2272783) FECH mRNA. | 2016-05-05 |
| 20160122768 | AUTOIMMUNE DISEASE TREATMENTS - There are provided, inter alia, methods and compositions to treat autoimmune disease including invasiveness of fibroblast-like synoviocytes in rheumatoid arthritis. | 2016-05-05 |
| 20160122769 | METHOD OF SCREENING FOR CHAPERONIN MODULATOR - The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target. Furthermore, by using the screened material, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease may be effectively prevented or treated without concern for cell death due to autophagy, which is the existing method of removing protein aggregate. | 2016-05-05 |
| 20160122770 | TREATMENT OF HYPERHIDROSIS - The present invention relates to a composition for reducing sweating in humans, characterized in that said composition comprises a compound capable of reduction of ITPR2 protein function and reduction of levels of ITPR2 mRNA and/or ITPR2 protein, and optionally pharmaceutically acceptable carriers and/or excipients, as well as to methods of treatment and specific siRNA molecules and their use in therapy. | 2016-05-05 |
| 20160122771 | Multiple Inducible Gene Regulation System - The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes. | 2016-05-05 |
| 20160122772 | Production of Polypeptides Without Secretion Signal in Bacillus - The present invention relates to a method of producing a natively non-secreted polypeptide without a secretion signal in a | 2016-05-05 |
| 20160122773 | ALTERED PIGMENT DEPOSITION IN TAGETES PATULA - The invention provides | 2016-05-05 |
| 20160122774 | A METHOD FOR PRODUCING PRECISE DNA CLEAVAGE USING CAS9 NICKASE ACTIVITY - The present invention is in the field of a method for genome engineering based on the type II CRISPR system, particularly a method for improving specificity and reducing potential off-site. The method is based on the use of nickase architectures of Cas9 and single or multiple crRNA(s) harboring two different targets lowering the risk of producing off-site cleavage. The present invention also relates to polypeptides, polynucleotides, vectors, compositions, therapeutic applications related to the method described here. | 2016-05-05 |
| 20160122775 | PLANT WITH ALTERED CONTENT OF STEROIDAL GLYCOALKALOIDS - The present invention relates to genetically modified plants by key genes involved in the biosynthesis of steroidal alkaloids. These plants have altered content of steroidal (glyco)alkaloids. Solanaceous crop plants with reduced content of antinutritional steroidal glycoalkaloids are provided. | 2016-05-05 |
| 20160122776 | PLANT WITH REDUCED PROTEIN PRODUCTIVITY IN SEEDS AND METHOD FOR PRODUCING SAME - According to the present invention, a gene having a novel function that can cause an increase or decrease in seed protein content is searched for. A chimeric protein obtained by fusing a transcription factor consisting of a protein comprising an amino acid sequence shown in any of the even-numbered SEQ ID NOS: 1 to 76 and a functional peptide capable of converting an arbitrary transcription factor into a transcriptional repressor or a transcription factor consisting of a protein comprising an amino acid sequence shown in any of the even-numbered SEQ ID NOS: 77 to 84 is expressed in a plant. | 2016-05-05 |
| 20160122777 | INFLUENZA VIRUS-LIKE PARTICLE PRODUCTION IN PLANTS - A method of producing a virus like particle (VLP) in a plant comprising modified hemagglutinin is provided. The method comprises introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a nucleotide sequence encoding a modified influenza hemagglutinin (HA) protein into the plant, or portion of the plant, the modified HA protein comprises a modified proteolytic loop. Followed by incubating the plant or portion of the plant under conditions that permit the expression of the nucleic acids, thereby producing the VLP. The modified proteolytic loop may comprise one or more protease cleavage sites exhibiting reduced or abolished cleavage by a protease. The nucleotide sequence encoding the HA may be selected from the group consisting of B HA, C, H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, and H16. Also described is a virus like particle (VLP) produced by the method, and plants expressing the VLP. The virus like particle (VLP) may comprise plant-specific N-glycans, or modified N-glycans. | 2016-05-05 |
| 20160122778 | STRESS TOLERANT PLANTS AND METHODS THEREOF - The present invention provides a method and DNA molecules that when expressed in a plant produces transgenic plants with improved abiotic stress tolerance. The invention includes plant expression vectors comprising the DNA molecules, and plants containing such DNA molecules. | 2016-05-05 |
| 20160122779 | Plants Having Increased Resistance To Pathogens And Method For Producing Said Plants - The invention relates to a plant having increased resistance to pathogens, wherein the protein SOBIR1 from | 2016-05-05 |
| 20160122780 | GENE EXPRESSION SYSTEM USING ALTERNATIVE SPLICING IN INSECTS - A polynucleotide expression system is provided that is capable of alternative splicing of RNA transcripts of a polynucleotide sequence to be expressed in an organism. | 2016-05-05 |
| 20160122781 | AFFENADENOVIRUS (GORILLA) OR ADENOVIRAL VECTORS AND METHODS OF USE - The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein. | 2016-05-05 |
| 20160122782 | METHODS FOR TRANSDUCTION AND CELL PROCESSING - Provided are methods, systems, and kits for cell processing, e.g., for therapeutic use, such as for adoptive cell therapy. The provided methods include transduction methods, in which cells and virus are incubated under conditions that result in transduction of the cells with a viral vector. The incubation in some embodiments is carried out in an internal cavity of a generally rigid centrifugal chamber, such as a cylindrical chamber made of hard plastic, the cavity of which may have a variable volume. The methods include other processing steps, including those carried out in such a chamber, including washing, selection, isolation, culture, and formulation. In particular, the disclosure relates to method providing advantages over available processing methods, such as available methods for large-scale processing. Such advantages include, for example, reduced cost, streamlining, increased efficacy, increased safety, and increased reproducibility among different subjects and conditions. | 2016-05-05 |
| 20160122783 | Genes and Uses for Plant Enhancement - Transgenic seed for crops with enhanced agronomic traits are provided by trait-improving recombinant DNA in the nucleus of cells of the seed where plants grown from such transgenic seed exhibit one or more enhanced traits as compared to a control plant. Of particular interest are transgenic plants that have increased yield. The present invention also provides recombinant DNA molecules for expression of a protein, and recombinant DNA molecules for suppression of a protein. | 2016-05-05 |
| 20160122784 | RECOMBINANT YEAST AND METHOD FOR PRODUCING ETHANOL USING THE SAME - The invention is intended to improve xylose assimilation ability and ethanol fermentation ability in a xylose-assimilating yeast into which a xylose isomerase gene has been introduced. The amount of NADH produced by the recombinant yeast into which the xylose isomerase gene had been introduced as a result of the enzymatic reaction of acetohydroxy acid reductoisomerase is lowered. | 2016-05-05 |
| 20160122785 | METHOD OF PRODUCING ETHANOL USING CONTINUOUS CULTURE AND CONTINUOUS CULTURE APPARATUS - A method of producing ethanol includes: measuring a xylose concentration in a culture fluid that contains microorganisms having xylose utilizing ability, the culture fluid including a culture medium that contains saccharides derived from lignocellulose; and performing an addition control in which an additional culture medium is added to the culture fluid to conduct a continuous culture of the microorganisms, the additional culture medium containing saccharides derived from lignocellulose. | 2016-05-05 |
| 20160122786 | COMPOSITIONS AND METHODS FOR GENERATION OF BIOFUELS - Provided herein are compositions and method for generation of biofuels. In particular, provided herein are modified bacteria for use in processing intermediates of algae biomass processing. | 2016-05-05 |
| 20160122787 | FERMENTATION PROCESS FOR THE PRODUCTION OF LIPIDS - The invention provides methods and systems for the production of lipid products from a gaseous substrate using a two stage fermentation process. The method comprises providing a gaseous substrate comprising CO, CO | 2016-05-05 |
| 20160122788 | CONTINUOUS PRODUCTION METHOD FOR 5-AMINOLEVULINIC ACID BY USING PHOTOSYNTHETIC MEMBRANE VESICLE - A method of continuously producing 5-aminolevulinic acid employs the photosynthetic bacteria-derived photosynthetic membrane vesicle, succinyl-CoA synthetase, and 5-aminolevulinic acid synthase. The enzymatic synthesis of 5-aminolevulinic acid directly from succinic acid and glycine may be simple, but the synthesis is not inexpensive due to the supply of ATP and CoA, which are relatively expensive reactants. The photosynthetic membrane vesicle is used together with succinyl-CoA synthetase and 5-aminolevulinic acid synthase, thereby enabling the re-use of adenosine diphosphate or CoA in reaction. Accordingly, relatively expensive 5-aminolevulinic acid can be efficiently produced at low manufacturing costs from succinic acid and glycine. | 2016-05-05 |
| 20160122789 | Microalgae of the Genus Euglena, Method for Producing Polysaccharides, and Method for Producing Organic Compound - Provided are microalgae of the genus | 2016-05-05 |
| 20160122790 | PROCESS OF SCALE PRODUCTION AND PURIFICATION OF BACTERIAL CELLULOSE OBTAINED BY GLUCOSE POLYMERIZATION FROM SUGARS OF RENEWABLE SOURCES VIA BIOTECHNOLOGY THROUGH THE PROPAGATION OF GLUCONOACETOBACTER HANSENII LMSPE IN REACTORS AND OBTAINMENT OF PURIFIED CELLULOSE FOR APPLICATION IN HEALTH, PHARMACOTECHNICAL AND COSMETIC DERMATOLOGY AREAS - A process of scale production and purification of bacterial cellulose obtained by glucose polymerization from sugars of renewable sources via biotechnology through the propagation of | 2016-05-05 |
| 20160122791 | HYPERTHERMOSTABLE ENDOGLUCANASE BELONGING TO GH FAMILY 12 - A hyperthermostable endoglucanase including an endoglucanase catalytic domain, the endoglucanase catalytic domain including:
| 2016-05-05 |
| 20160122792 | HIGH EFFICIENCY, SMALL VOLUME NUCLEIC ACID SYNTHESIS - The disclosure generally relates to compositions and methods for the production of nucleic acid molecules. In some aspects, the invention allows for the microscale generation of nucleic acid molecules, optionally followed by assembly of these nucleic acid molecules into larger molecules. In some aspects, the invention allows for efficient production of nucleic acid molecules (e.g., large nucleic acid molecules such as genomes). | 2016-05-05 |
| 20160122793 | Fusion Protease - This invention relates to novel bifunctional fusion proteases useful for manufacturing a mature protein from a fusion protein. More specifically the present invention relates to bifunctional fusion proteases comprising a picornaviral 3C protease and a Xaa-Pro-dipeptidyl aminopeptidase. | 2016-05-05 |
| 20160122794 | SYSTEM, METHOD AND APPARATUS FOR PATHOGEN DETECTION - Systems and methods for pathogen detection are described. A method for pathogen detection comprises collecting a sample from a subject, combining the sample with amplification substances, performing detection operations on the combined sample, analyzing the detection signals, and disposing of the combined sample. Embodiments of an apparatus for pathogen detection comprise a microfluidic disk having a plurality of reaction chambers for combining a sample and amplification substances. Further described apparatuses for pathogen detection comprise a storage unit, a sensor unit and a disposal unit. | 2016-05-05 |
| 20160122795 | MICROORGANISM CULTURING MATERIAL AND METHOD FOR DETECTING MICROORGANISMS - A sheet-form microorganism culturing material including a water-soluble polymer compound layer and a porous matrix layer in which both high moisture retention capability and colony color formation capability are satisfied. | 2016-05-05 |
| 20160122796 | METHOD FOR EXAMINING MICROORGANISMS - A method for examining microorganisms has a sampling preparation step including a fluorescence staining step of stirring and mixing certain amounts of a sample and a fluorescence staining reagent, a still standing step of leaving the solution after the fluorescence staining step to still stand for a certain time, and a dilution step of diluting the solution after the still standing step with a liquid that emits no fluorescence. | 2016-05-05 |
| 20160122797 | MAGNETIC SEPARATION PROCESS USING CARBOXYL-FUNCTIONALIZED SUPERPARAMAGNETIC NANOCLUSTERS - A process including: contacting a plurality of carboxyl-functionalized superparamagnetic nanoclusters with a liquid sample potentially comprising at least one microorganism strain; magnetically separating at least some of the carboxyl-functionalized superparamagnetic nanoclusters from at least a portion of the liquid sample; and, assaying the magnetically-separated superparamagnetic nanoclusters for evidence of the at least one microorganism strain having been non-specifically bound thereto. | 2016-05-05 |
| 20160122798 | SYSTEMS AND METHODS FOR ASEPTIC SAMPLING - A sampling assembly configured to be coupled to a sample source and facilitate aseptic sampling at one or more instances in time is provided. Further, the sampling assembly includes a first conduit having first and second ports, where the first port is configured to be coupled to the sample source. The sampling assembly also includes a plurality of sub-conduits having corresponding sub-ports, where each of the plurality of sub-conduits is operatively coupled to the first conduit at respective connector junctions. Also, each of the sub-ports is in fluidic communication with the first conduit. The sampling assembly also includes a plurality of sampling kits and one or more pumping devices. Further, each sampling kit is operatively coupled to a respective sub-port of a corresponding sub-conduit. Moreover, the one or more pumping devices are operatively and aseptically coupled to the second port of the first conduit. | 2016-05-05 |
